You Made the IMF’s Blood Cancer Awareness Month a Success!

As September draws to a close, the IMF wants to thank each of you for making this year’s Blood Cancer Awareness Month a huge success. Through your efforts, the IMF is very close to reaching our goal of connecting with nearly 20 million people in many countries around the globe. Can you help us reach our goal? It's simple. Like or share our posts on our social media channels or download graphics to share from the button below. With your help, we can truly say that more people kNOw MYELOMA. 

Living Well with Myeloma: Can Nutrition Improve Quality of Life and Outcomes in Myeloma?

Join us for the "Living Well with Myeloma" webinar on October 12, 2023, at 4:00 p.m. PST with Dr. Urvi A. Shah. As myeloma survival rates rise, discover how nutrition and lifestyle interventions can further improve outcomes. Dr. Shah will delve into the scientific evidence behind dietary guidance, drawing from epidemiologic studies and clinical trials. Learn how diet influences cancer through the microbiome, metabolism, and the immune system. The webinar will wrap up with practical tips to enhance dietary habits. Engage in a summary discussion and a Live Q&A, gaining valuable insights to empower yourself. 

Lace Up Your Sneakers for the 11th Annual Miracles for Myeloma 5K Run/Walk

Lace up your sneakers and join us for an incredible cause at the 11th Annual Miracles for Myeloma 5K Run/Walk. We're thrilled to invite you to a day filled with hope, inspiration, and community as we gather on October 14 in Oak Ridge Park in Clark, New Jersey. You can join us at 10:00 a.m. EST on that day to race in person, or you can log your miles and race virtually. Whether you're a seasoned runner or just love a leisurely stroll, this event is for everyone. By participating, you're making a direct impact on the lives of those affected by myeloma and contributing to groundbreaking research that brings us closer to a cure. Contact Ron Pask at 732-574-9182 or [email protected] to learn more. See you at the starting line!

Calling All High-Risk Multiple Myeloma Patients: Support Options for You!

If you're living with high-risk myeloma, you don't have to navigate this journey on your own. We've created a supportive community just for you. Our virtual support group will kick off on October 17, 2023, at 4:00 p.m. PST | 7:00 p.m. EST. Join us for an informative session featuring IMF Chief Medical Officer Dr. Joseph Mikhael, who will delve into the criteria used to identify high-risk myeloma cases. If you're interested in participating and would like more information, contact us at [email protected]. For a comprehensive overview, visit HRMM.support.myeloma.org. Remember, you're not alone—our community is here for you!

Las Voces de Mieloma Support Group (Spanish-Virtual)

Join Las Voces de Mieloma Support Group (Spanish/Virtual), on Tuesday, October 17, 10:00 a.m.–11:00 a.m. (Pacific)

Guest speaker:  Jesus G. Berdeja, MD
Director, Multiple Myeloma Research, Tennessee Oncology — Nashville, Tennessee

Jesus G. Berdeja received his undergraduate degree from Stanford University and medical degree from Harvard University.  He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore. Prior to joining the staff at Tennessee Oncology and the Sarah Cannon Research Institute, Dr. Berdeja held appointments in the Stem Cell and Bone Marrow Transplant Program and the Division of Hematology and Oncology at Loma Linda University in Loma Linda, California.

Dr. Berdeja specializes in clinical hematology, with a focus on multiple myeloma and has been certified a Diplomate in hematology by the American Board of Internal Medicine.  He is a frequent peer reviewer for many prominent medical journals.  Additionally, he is an active member of several professional organizations, including the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, the International Myeloma Working Group and the Clinical Trials Myeloma Intergroup Committee.

An active researcher, Dr. Berdeja has been the principal investigator of many funded clinical trials in the field of multiple myeloma. He has published extensively in the peer-reviewed literature and is a frequent invited lecturer.

For any questions, please email [email protected].

Las Voces de Mieloma Grupo de Apoyo (Virtual/Español)

Las Voces de Mieloma Grupo de Apoyo (en Español/Virtual), Martes, 17 de Octubr, 10:00 a.m.-11:00 a.m. (Tiempo Pacífico).

Invitada Especial: Jesus G. Berdeja, MD

Director, Investigación del Mieloma Múltiple, Tennessee Oncology — Nashville, Tennessee

Jesús G. Berdeja recibió su licenciatura de la Universidad de Stanford y su título de médico de la Universidad de Harvard. Completó su internado y residencia en el Departamento de Medicina Interna de la Universidad de California en San Francisco y becas en oncología médica y hematología en la Facultad de Medicina de la Universidad Johns Hopkins en Baltimore. Antes de unirse al personal de Tennessee Oncology y de Sarah Cannon Research Institute, el Dr. Berdeja ocupó cargos en el Programa de Trasplante de Células Madre y Médula Ósea y en la División de Hematología y Oncología de la Universidad de Loma Linda en Loma Linda, California.  

El Dr. Berdeja se especializa en hematología clínica, con un enfoque en el mieloma múltiple y ha sido certificado como Diplomado en hematología por la Junta Americana de Medicina Interna. Es un revisor frecuente de muchas revistas médicas prominentes. Además, es miembro activo de varias organizaciones profesionales, incluyendo la Sociedad Internacional de Mieloma, la Sociedad Americana de Oncología Clínica, la Sociedad Americana de Hematología, el Grupo de Trabajo Internacional de Mieloma y el Comité Intergrupal de Mieloma de Ensayos Clínicos.

Un investigador activo, el Dr. Berdeja ha sido el investigador principal de muchos ensayos clínicos financiados en el campo del mieloma múltiple. Ha publicado extensamente en la literatura revisada por pares y es un ponente invitado frecuente.

 Para preguntas, envíe un correo electrónoco a: [email protected].

Watch This Video on Bispecific Antibodies and Late Side Effects

IMF Chief Medical Officer Dr. Joseph Mikhael talks about the late side effects of bispecific antibodies, including infections, low white blood cell counts, and hypogammaglobulinemia.

#ASKDRDURIE | Dr. Durie's Weekly Web Video Series

What is the monoclonal antibody TALVEY™ (talquetamab)?